Literature DB >> 27247321

Prolonged disease-free survival in elderly relapsed diffuse large B-cell lymphoma patients treated with lenalidomide plus rituximab.

Pier Luigi Zinzani1, Cinzia Pellegrini2, Lisa Argnani2, Alessandro Broccoli2.   

Abstract

Entities:  

Keywords:  diffuse large B-cell lymphoma; elderly; lenalidomide; relapsed; rituximab

Mesh：

Substances：

Year:  2016        PMID： 27247321      PMCID： PMC5060037          DOI： 10.3324/haematol.2016.147256

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  10 in total

Review 1.  Relapsed/refractory diffuse large B-cell lymphoma.

Authors:  Jonathan W Friedberg
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2011

Review 2.  Relapses, treatments and new drugs.

Authors:  Nicolas Mounier; Christian Gisselbrecht
Journal:  Best Pract Res Clin Haematol       Date:  2012-02-04       Impact factor: 3.020

3.  Higher response to lenalidomide in relapsed/refractory diffuse large B-cell lymphoma in nongerminal center B-cell-like than in germinal center B-cell-like phenotype.

Authors:  Francisco J Hernandez-Ilizaliturri; George Deeb; Pier L Zinzani; Stefano A Pileri; Farhana Malik; William R Macon; Andre Goy; Thomas E Witzig; Myron S Czuczman
Journal:  Cancer       Date:  2011-04-14       Impact factor: 6.860

4.  Long-term efficacy of the combination of lenalidomide and rituximab in elderly relapsed/refractory diffuse large B-cell lymphoma patients.

Authors:  Pier Luigi Zinzani; Cinzia Pellegrini; Enrico Derenzini; Lisa Argnani; Stefano Pileri
Journal:  Hematol Oncol       Date:  2013-04-26       Impact factor: 5.271

5.  Revised response criteria for malignant lymphoma.

Authors:  Bruce D Cheson; Beate Pfistner; Malik E Juweid; Randy D Gascoyne; Lena Specht; Sandra J Horning; Bertrand Coiffier; Richard I Fisher; Anton Hagenbeek; Emanuele Zucca; Steven T Rosen; Sigrid Stroobants; T Andrew Lister; Richard T Hoppe; Martin Dreyling; Kensei Tobinai; Julie M Vose; Joseph M Connors; Massimo Federico; Volker Diehl
Journal:  J Clin Oncol       Date:  2007-01-22       Impact factor: 44.544

6.  Oral lenalidomide with rituximab in relapsed or refractory diffuse large cell, follicular and transformed lymphoma: a phase II clinical trial.

Authors:  M Wang; N Fowler; N Wagner-Bartak; L Feng; J Romaguera; S S Neelapu; F Hagemeister; M Fanale; Y Oki; B Pro; J Shah; S Thomas; A Younes; C Hosing; L Zhang; K J Newberry; M Desai; N Cheng; M Badillo; M Bejarano; Y Chen; K H Young; R Champlin; L Kwak; L Fayad
Journal:  Leukemia       Date:  2013-04-02       Impact factor: 11.528

7.  An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma.

Authors:  T E Witzig; J M Vose; P L Zinzani; C B Reeder; R Buckstein; J A Polikoff; R Bouabdallah; C Haioun; H Tilly; P Guo; D Pietronigro; A L Ervin-Haynes; M S Czuczman
Journal:  Ann Oncol       Date:  2011-01-12       Impact factor: 32.976

8.  Combination of lenalidomide and rituximab in elderly patients with relapsed or refractory diffuse large B-cell lymphoma: a phase 2 trial.

Authors:  Pier Luigi Zinzani; Cinzia Pellegrini; Letizia Gandolfi; Vittorio Stefoni; Federica Quirini; Enrico Derenzini; Alessandro Broccoli; Lisa Argnani; Stefano Pileri; Michele Baccarani
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2011-05-04

9.  Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray.

Authors:  Christine P Hans; Dennis D Weisenburger; Timothy C Greiner; Randy D Gascoyne; Jan Delabie; German Ott; H Konrad Müller-Hermelink; Elias Campo; Rita M Braziel; Elaine S Jaffe; Zenggang Pan; Pedro Farinha; Lynette M Smith; Brunangelo Falini; Alison H Banham; Andreas Rosenwald; Louis M Staudt; Joseph M Connors; James O Armitage; Wing C Chan
Journal:  Blood       Date:  2003-09-22       Impact factor: 22.113

10.  Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma.

Authors:  Peter H Wiernik; Izidore S Lossos; Joseph M Tuscano; Glen Justice; Julie M Vose; Craig E Cole; Wendy Lam; Kyle McBride; Kenton Wride; Dennis Pietronigro; Kenichi Takeshita; Annette Ervin-Haynes; Jerome B Zeldis; Thomas M Habermann
Journal:  J Clin Oncol       Date:  2008-07-07       Impact factor: 44.544
  10 in total
  9 in total

Review 1.  Chimeric antigen receptor (CAR) T-cell therapy for people with relapsed or refractory diffuse large B-cell lymphoma.

Authors:  Moritz Ernst; Annika Oeser; Burcu Besiroglu; Julia Caro-Valenzuela; Mohamed Abd El Aziz; Ina Monsef; Peter Borchmann; Lise J Estcourt; Nicole Skoetz; Marius Goldkuhle
Journal:  Cochrane Database Syst Rev       Date:  2021-09-13

Review 2.  Current Progress in EBV-Associated B-Cell Lymphomas.

Authors:  Yonggang Pei; Alexandria E Lewis; Erle S Robertson
Journal:  Adv Exp Med Biol       Date:  2017       Impact factor: 2.622

Review 3.  Challenges and Opportunities in the Management of Diffuse Large B-Cell Lymphoma in Older Patients.

Authors:  Mengyang Di; Scott F Huntington; Adam J Olszewski
Journal:  Oncologist       Date:  2020-12-09       Impact factor: 5.837

Review 4.  How I manage patients with relapsed/refractory diffuse large B cell lymphoma.

Authors:  Christian Gisselbrecht; Eric Van Den Neste
Journal:  Br J Haematol       Date:  2018-05-29       Impact factor: 6.998

Review 5.  New agents and regimens for diffuse large B cell lymphoma.

Authors:  Liang Wang; Lin-Rong Li; Ken H Young
Journal:  J Hematol Oncol       Date:  2020-12-14       Impact factor: 17.388

Review 6.  Current options and future perspectives in the treatment of patients with relapsed/refractory diffuse large B-cell lymphoma.

Authors:  Fabian Frontzek; Imke Karsten; Norbert Schmitz; Georg Lenz
Journal:  Ther Adv Hematol       Date:  2022-06-28

Review 7.  Comparison of Access to Novel Drugs for Lymphoma and Chronic Lymphocytic Leukemia Between India and the United States.

Authors:  Vishwanath Sathyanarayanan; Christopher R Flowers; Swaminathan P Iyer
Journal:  JCO Glob Oncol       Date:  2020-07

8.  Application of Lenalidomide on Diffused Large B-cell Lymphoma: Salvage, Maintenance, and Induction Treatment.

Authors:  Li-Yangxue Ma; Li Su
Journal:  Chin Med J (Engl)       Date:  2018-10-20       Impact factor: 2.628

9.  Phase I, multicenter, dose-escalation study of avadomide in adult Japanese patients with advanced malignancies.

Authors:  Kiyohiko Hatake; Takaaki Chou; Toshihiko Doi; Yasuhito Terui; Harumi Kato; Takayuki Hirose; Sachiko Seo; Michael Pourdehnad; Yumi Ogaki; Hiroshi Fujimoto; Patrick R Hagner; Kazuhito Yamamoto
Journal:  Cancer Sci       Date:  2020-11-26       Impact factor: 6.518
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.